Mofezolac acts via selective inhibition of the
cyclooxygenaseCOX-1 and consequent suppression of
prostaglandin synthesis.[5] It is the most potent and selective reversible COX-1 inhibitor.[6] Studies of
ovine COX-1 in complex with mofezolac indicate that the drug forms a combination of electrostatic, H-bond, hydrophobic, and van der Waals contacts with the enzyme
active site channel, contributing to mofezolac's high binding affinity.[7]
Mofezolac belongs to the class of
isoxazoles and is a substrate of
CYP2C9.[8]
It is manufactured and marketed by
Nipro ES Pharma Co., Ltd.[1]
^"Pharmaceuticals and Medical Devices Safety Information" (381). Translated by Pharmaceuticals and Medical Devices Agency. Japan Ministry of Health, Labour and Welfare. March 2021. {{
cite journal}}: Cite journal requires |journal= (
help)
^Pati ML, Vitale P, Ferorelli S, Iaselli M, Miciaccia M, Boccarelli A, et al. (February 2019). "Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability". European Journal of Medicinal Chemistry. 164: 59–76.
doi:
10.1016/j.ejmech.2018.12.029.
hdl:11586/227733.
PMID30590258.
S2CID58648199.